Orchid Pharma, erstwhile Orchid Chemicals and Pharmaceuticals Ltd, on Tuesday informed the exchanges that it has received abbreviated new drug application (ANDA) approval from the US FDA for Risedronate Sodium tablets USP, 30 mg and 35 mg. The drug (bisphosphonate) is used for the treatment and prevention of osteoporosis, the statement added. Shareholders of the loss-making pharma firm will closely monitor further developments.